This oncogenic potential in conjunction with the aberrant expression and/or activation of EGFR, which has been reported in a range of human malignancies including breast cancer, provides a strong rationale for targeting this growth factor receptor [6,7]. This evidence concerns the gene EGFR and breast carcinoma.